The stock of Biogen Inc (BIIB) has gone down by -6.66% for the week, with a -9.15% drop in the past month and a -24.06% drop in the past quarter. The volatility ratio for the week is 2.90%, and the volatility levels for the past 30 days are 2.45% for BIIB. The simple moving average for the last 20 days is -4.50% for BIIB stock, with a simple moving average of -27.18% for the last 200 days.
Is It Worth Investing in Biogen Inc (NASDAQ: BIIB) Right Now?
Biogen Inc (NASDAQ: BIIB) has a price-to-earnings ratio of 12.92x that is above its average ratio. Additionally, the 36-month beta value for BIIB is -0.08. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 6 rating it as “overweight,” 16 rating it as “hold,” and 0 rating it as “sell.”
The public float for BIIB is 144.68M and currently, short sellers hold a 2.54% ratio of that float. The average trading volume of BIIB on January 15, 2025 was 1.49M shares.
BIIB) stock’s latest price update
The stock of Biogen Inc (NASDAQ: BIIB) has decreased by -4.74 when compared to last closing price of 150.18. Despite this, the company has experienced a -6.66% fall in its stock price over the last five trading sessions. reuters.com reported 2025-01-14 that Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company’s CEO said.
Analysts’ Opinion of BIIB
Many brokerage firms have already submitted their reports for BIIB stocks, with Piper Sandler repeating the rating for BIIB by listing it as a “Neutral.” The predicted price for BIIB in the upcoming period, according to Piper Sandler is $138 based on the research report published on January 02, 2025 of the current year 2025.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see BIIB reach a price target of $164, previously predicting the price at $230. The rating they have provided for BIIB stocks is “Market Perform” according to the report published on December 20th, 2024.
Stifel gave a rating of “Hold” to BIIB, setting the target price at $175 in the report published on December 16th of the previous year.
BIIB Trading at -9.42% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.27% of loss for the given period.
Volatility was left at 2.45%, however, over the last 30 days, the volatility rate increased by 2.90%, as shares sank -7.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.04% lower at present.
During the last 5 trading sessions, BIIB fell by -6.66%, which changed the moving average for the period of 200-days by -33.87% in comparison to the 20-day moving average, which settled at $149.80. In addition, Biogen Inc saw -6.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from Singhal Priya, who sale 110 shares at the price of $157.21 back on Dec 09 ’24. After this action, Singhal Priya now owns 5,426 shares of Biogen Inc, valued at $17,293 using the latest closing price.
Singhal Priya, the Officer of Biogen Inc, proposed sale 110 shares at $157.21 during a trade that took place back on Dec 09 ’24, which means that Singhal Priya is holding shares at $17,293 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- 0.21 for the present operating margin
- 0.72 for the gross margin
The net margin for Biogen Inc stands at 0.17. The total capital return value is set at 0.09. Equity return is now at value 10.47, with 5.72 for asset returns.
Based on Biogen Inc (BIIB), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at 0.32. The debt to equity ratio resting at 0.41. The interest coverage ratio of the stock is 7.59.
Currently, EBITDA for the company is 2.38 billion with net debt to EBITDA at 1.71. When we switch over and look at the enterprise to sales, we see a ratio of 2.74. The receivables turnover for the company is 4.73for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
In conclusion, Biogen Inc (BIIB) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
